Madrigal Pharmaceuticals, INC Form 4 insider transactions

Director Jacqualyn A. Fouse reports the acquisition of restricted stock units and stock options in Madrigal Pharmaceuticals.

William Sibold, CEO of Madrigal Pharmaceuticals, was granted restricted stock units and stock options on March 5, 2025, according to a Form 4 filing.

Mardi Dier, SVP and CFO of Madrigal Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Senior VP Robert E. Waltermire reports exercising stock options and selling shares of Madrigal Pharmaceuticals common stock on March 5, 2025.

Rebecca Taub, a key executive at Madrigal Pharmaceuticals, reports the acquisition of stock options and restricted stock units, along with indirect ownership through SQN, LLC.

Shannon Kelley, General Counsel of Madrigal Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Shannon T. Kelley, General Counsel of Madrigal Pharmaceuticals, sold 415 shares of common stock at $335 per share on March 3, 2025, according to a Form 4 filing.

Mardi Dier, SVP and CFO of Madrigal Pharmaceuticals, reported the sale of common stock to cover tax obligations and pursuant to a pre-arranged trading plan.

Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, sold shares of common stock on March 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Robert E. Waltermire, a Senior VP at Madrigal Pharmaceuticals, sold shares of common stock on February 28, 2025.

Director Kenneth Bate reports exercising stock options and selling shares of Madrigal Pharmaceuticals on February 27, 2025.

Madrigal Pharmaceuticals' CEO, William John Sibold, earned 50,000 shares of common stock on February 27, 2025, after meeting performance conditions tied to restricted stock units.

Director James M. Daly of Madrigal Pharmaceuticals reports the exercise of stock options and subsequent sale of common stock on February 27, 2025.

Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, sold 347 shares of common stock on January 24, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Madrigal Pharmaceuticals CEO William John Sibold sold 1,584 shares of common stock to cover tax obligations related to vesting restricted stock units.

Rebecca Taub, a Madrigal Pharmaceuticals executive, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Robert E. Waltermire, Senior VP of Madrigal Pharmaceuticals, sold 103 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Madrigal Pharmaceuticals' General Counsel, Shannon T. Kelley, sold 277 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Madrigal Pharmaceuticals executive sold 442 shares of common stock at $273.41 per share to cover tax obligations related to vesting restricted stock units.

Rebecca Taub, a Madrigal Pharmaceuticals executive, sold 1,689 shares of common stock to cover tax obligations related to vesting restricted stock units.

Madrigal Pharmaceuticals director Fred B. Craves sold a portion of his holdings in multiple transactions on December 3, 2024.

Director Fred B. Craves of Madrigal Pharmaceuticals sold a total of 3,400 shares of common stock in multiple transactions on November 25, 2024.

Madrigal Pharmaceuticals' Chief Commercial Officer, Carole Huntsman, sold 688 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Director Richard S. Levy exercised stock options and sold shares of Madrigal Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Director Richard S. Levy exercised stock options and sold shares of Madrigal Pharmaceuticals (MDGL) on November 1, 2024, according to a Form 4 filing with the SEC.

Dr. Fred B. Craves, a director of Madrigal Pharmaceuticals, reported a transaction involving company stock, including a gift of 15,000 shares.

William John Sibold, CEO of Madrigal Pharmaceuticals, sold 6,363 shares of common stock on September 9, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Shannon T. Kelley, General Counsel of Madrigal Pharmaceuticals, reports acquisition of common stock and stock options.

Director Fred B. Craves reports acquisition of restricted stock units and stock options in Madrigal Pharmaceuticals, along with adjustments to indirectly held shares.